α-Lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity

NeuroReport

Volumn 10, Issue 17, 1999, Pages 3675-3680

  Aguirre, Norberto ^a   Barrionuevo, Meritxell ^a   Ramírez, María J ^a   Del Río, Joaquín ^a   Lasheras, Berta ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

3,4 Methylenedioxymethamphetamine (MDMA, Ecstasy); 5 HT (serotonin, 5 hydroxytryptamine); Glial fibrillary acidic protein (GFAP); Lipoic acid (thiotic acid)

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; SEROTONIN; SEROTONIN TRANSPORTER; THIOCTIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTHERMIA; IMMUNOREACTIVITY; MALE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 0033607450     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199911260-00039     Document Type: Article

References (25)

1. 1. White SR, Obradovic T, Imel KM et al. Progr Neurobiol 49, 455-479 (1996).
2. 2. Miller DB, and O'Callaghan JP. Mol Neurobiol 11, 177-192 (1995).
3. 3. Colado MI and Green AR. Eur J Pharmacol 280, 343-346 (1995).
4. 4. Colado MI, O'Shea E, Granados R et al. Br J Pharmacol 121, 889-900 (1997).
5. 5. Sprague JE, Shannon LE and Nichols DE. Neorotoxicology 19, 427-442 (1998).
6. 6. Jacob S, Henriksen EJ, Schiemann AL et al. Arzn Forsch 45, 872-874 (1995).
7. 7. Packer L, Tritschler HJ and Wessel K. Free Rad Biol Med 22, 359-378 (1997).
8. 8. Roy S and Packer L. Biofactors 8, 17-21 (1998).
9. 9. Fartel GM and Seiden LS. J Pharmacol Exp Ther 272, 860-867 (1995).
10. 10. Malberg JE, Sabol KE and Seiden LS. J Pharmacol Exp Ther 278, 258-267 (1996).
11. 11. Colado MI, Granados R, O'Shea E et al. Br J Pharmacol 124, 479-484 (1998).
12. 12. Pérez-Otaño I, Herrero MT, Oset C et al. Brain Res 567, 127-132 (1991).
13. 13. Marcusson JO, Bergström M, Eriksson K et al. J Neurochem 50, 1783-1790 (1988).
14. 14. Battaglia G, Yeh SY, O'Hearn E et al. J Pharmacol Exp Ther 242, 911-916 (1987).
15. 15. Norton WT, Aquino DA, Hozumi I et al. Neurochem Res 17, 877-885 (1992).
16. 16. O'Callaghan JP. Ann NY Acad Sci 679, 195-210 (1993).
17. 17. Steinbusch HWM. Neuroscience 6, 557-618 (1981).
18. 18. Dusart I, Marty S and Peschanski M. Neuroscience 45, 541-549 (1991).
19. 19. O'Shea E, Granados R, Esteban B et al. Neuropharmacology 37, 919-926 (1998).
20. 20. Hiramatsu M, Kumagai Y, Unger SE et al. J Pharmacol Exp Ther 254, 521-528 (1990).
21. 21. Poblete JC and Azmitia EC. Brain Res 680, 9-15 (1995).
22. 22. Lipton SA and Rosenberg PA. N Engl J Med 330, 613-622 (1994).
23. 23. Malberg JE and Seiden LS. J Neurosci 18, 5086-5094 (1998).
24. 24. Globus MY, Busto R, Lin B et al. J Neurochem 65, 1250-1256(1995).
25. 25. Kil HY, Zhang J and Piantadosi CA. J Cerebr Blood Flow Metab 16, 100-106 (1996).